Diagonal Bio
Diagonal Bio granted patent in Japan
At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia.
“The granted patent in Japan further strengthens our position and protection. We are continuously working to protect our platform and inventions from different angles.” - Karin Wehlin, CEO of Diagonal Bio AB (publ)
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.
| Datum | 2025-03-21, kl 14:00 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.